These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

626 related items for PubMed ID: 7815350

  • 1. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
    Gonzalez Vera W, Fournié-Zaluski MC, Pham I, Laboulandine I, Roques BP, Michel JB.
    J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
    [Abstract] [Full Text] [Related]

  • 2. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
    Pham I, Gonzalez W, el Amrani AI, Fournié-Zaluski MC, Philippe M, Laboulandine I, Roques BP, Michel JB.
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
    Gonzalez W, Beslot F, Laboulandine I, Fournié-Zaluski MC, Roques BP, Michel JB.
    J Pharmacol Exp Ther; 1996 Aug; 278(2):573-81. PubMed ID: 8768706
    [Abstract] [Full Text] [Related]

  • 4. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.
    Fournié-Zaluski MC, Gonzalez W, Turcaud S, Pham I, Roques BP, Michel JB.
    Proc Natl Acad Sci U S A; 1994 Apr 26; 91(9):4072-6. PubMed ID: 8171037
    [Abstract] [Full Text] [Related]

  • 5. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.
    Chatelain RE, Ghai RD, Trapani AJ, Odorico LM, Dardik BN, De Lombaert S, Lappe RW, Fink CA.
    J Pharmacol Exp Ther; 1998 Mar 26; 284(3):974-82. PubMed ID: 9495857
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ, Anastasopoulos F, Duncan AM, James GM, Kladis A, Briscoe TA.
    J Pharmacol Exp Ther; 1998 Nov 26; 287(2):567-77. PubMed ID: 9808682
    [Abstract] [Full Text] [Related]

  • 8. Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors.
    Seymour AA, Asaad MM, Abboa-Offei BE, Smith PL, Rogers WL, Dorso CR.
    J Pharmacol Exp Ther; 1996 Feb 26; 276(2):708-13. PubMed ID: 8632340
    [Abstract] [Full Text] [Related]

  • 9. Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models.
    Nagata S, Takeyama K, Fukuya F, Nagai R, Hosoki K, Nishimura K, Deguchi T, Karasawa T.
    Arzneimittelforschung; 1995 Aug 26; 45(8):853-8. PubMed ID: 7575746
    [Abstract] [Full Text] [Related]

  • 10. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
    Fournie-Zaluski MC, Coric P, Thery V, Gonzalez W, Meudal H, Turcaud S, Michel JB, Roques BP.
    J Med Chem; 1996 Jun 21; 39(13):2594-608. PubMed ID: 8691458
    [Abstract] [Full Text] [Related]

  • 11. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
    Wallis EJ, Ramsay LE, Hettiarachchi J.
    Clin Pharmacol Ther; 1998 Oct 21; 64(4):439-49. PubMed ID: 9797801
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms underlying the augmented responses of deoxycorticosterone acetate-salt hypertensive rats to neutral endopeptidase inhibitors.
    Hirata Y, Suzuki Y, Suzuki E, Hayakawa H, Kimura K, Goto A, Omata M, Minamino N, Kangawa K, Matsuo H.
    J Hypertens; 1994 Apr 21; 12(4):367-74. PubMed ID: 8064160
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
    Trippodo NC, Robl JA, Asaad MM, Bird JE, Panchal BC, Schaeffer TR, Fox M, Giancarli MR, Cheung HS.
    J Pharmacol Exp Ther; 1995 Nov 21; 275(2):745-52. PubMed ID: 7473162
    [Abstract] [Full Text] [Related]

  • 14. Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats.
    Gardiner SM, Kemp PA, Brunner-Ferber F, Bennett T.
    Br J Pharmacol; 1997 Dec 21; 122(8):1687-93. PubMed ID: 9422815
    [Abstract] [Full Text] [Related]

  • 15. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
    Fournié-Zaluski MC, Coric P, Turcaud S, Rousselet N, Gonzalez W, Barbe B, Pham I, Jullian N, Michel JB, Roques BP.
    J Med Chem; 1994 Apr 15; 37(8):1070-83. PubMed ID: 8164250
    [Abstract] [Full Text] [Related]

  • 16. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension.
    French JF, Anderson BA, Downs TR, Dage RC.
    J Cardiovasc Pharmacol; 1995 Jul 15; 26(1):107-13. PubMed ID: 7564349
    [Abstract] [Full Text] [Related]

  • 17. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.
    Roques BP.
    Pathol Biol (Paris); 1998 Mar 15; 46(3):191-200. PubMed ID: 9769915
    [Abstract] [Full Text] [Related]

  • 18. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
    Bralet J, Marie C, Mossiat C, Lecomte JM, Gros C, Schwartz JC.
    J Pharmacol Exp Ther; 1994 Jul 15; 270(1):8-14. PubMed ID: 8035346
    [Abstract] [Full Text] [Related]

  • 19. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase.
    French JF, Flynn GA, Giroux EL, Mehdi S, Anderson B, Beach DC, Koehl JR, Dage RC.
    J Pharmacol Exp Ther; 1994 Jan 15; 268(1):180-6. PubMed ID: 8301555
    [Abstract] [Full Text] [Related]

  • 20. Potentiation of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anesthetized dogs.
    Seymour AA, Sheldon JH, Smith PL, Asaad M, Rogers WL.
    J Pharmacol Exp Ther; 1994 Apr 15; 269(1):263-70. PubMed ID: 8169834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.